Silexion Therapeutics Corp (SLXN)

Currency in USD
7.240
-0.120(-1.63%)
Closed·
7.2400.000(0.00%)
·
SLXN Scorecard
Full Analysis
Operates with a significant debt burden
SLXN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
7.1607.420
52 wk Range
7.090346.950
Key Statistics
Prev. Close
7.36
Open
7.39
Day's Range
7.16-7.42
52 wk Range
7.09-346.95
Volume
10.87K
Average Volume (3m)
90.09K
1-Year Change
-99.43%
Book Value / Share
-37.33
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SLXN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
24.000
Upside
+231.49%
Members' Sentiments
Bearish
Bullish
ProTips
May have trouble making interest payments on debt

Silexion Therapeutics Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Silexion Therapeutics Corp Company Profile

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

Compare SLXN to Peers and Sector

Metrics to compare
SLXN
Peers
Sector
Relationship
P/E Ratio
−0.2x−3.2x−0.5x
PEG Ratio
-−0.090.00
Price/Book
−1.0x2.1x2.6x
Price / LTM Sales
-155.5x3.3x
Upside (Analyst Target)
231.5%449.5%40.3%
Fair Value Upside
Unlock0.2%5.1%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 24.000
(+231.49% Upside)

Earnings

Latest Release
Mar 18, 2025
EPS / Forecast
-288.11 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

SLXN Income Statement

People Also Watch

5.56
REPL
+3.93%
3.170
OPEN
+4.28%
2.5400
LIDR
-3.05%
7.040
ATNF
-7.49%
14.9100
INKT
-2.68%

FAQ

What Stock Exchange Does Silexion Therapeutics Trade On?

Silexion Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Silexion Therapeutics?

The stock symbol for Silexion Therapeutics is "SLXN."

What Is the Silexion Therapeutics Market Cap?

As of today, Silexion Therapeutics market cap is 4.06M.

What Is Silexion Therapeutics's Earnings Per Share (TTM)?

The Silexion Therapeutics EPS (TTM) is -395.36.

From a Technical Analysis Perspective, Is SLXN a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Silexion Therapeutics Stock Split?

Silexion Therapeutics has split 2 times.

How Many Employees Does Silexion Therapeutics Have?

Silexion Therapeutics has 13 employees.

What is the current trading status of Silexion Therapeutics (SLXN)?

As of 16 Aug 2025, Silexion Therapeutics (SLXN) is trading at a price of 7.24, with a previous close of 7.36. The stock has fluctuated within a day range of 7.16 to 7.42, while its 52-week range spans from 7.09 to 346.95.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.